Prostate Cancer

Results of Phase I Study Reach Primary End Point for mCRPC

May 14, 2020

Scott T. Tagawa, MD, MS, discusses a phase I dose-escalation study of actinium-225 in patients with progressive metastatic castration-resistant prostate cancer who had previously received at least 1 pathway inhibitor.

Cabazitaxel Impacts Sequencing Strategies in Prostate Cancer

May 07, 2020

Daniel J. George, MD, discusses how cabazitaxel can impact the sequencing approaches physicians use to treat patients with metastatic castration-resistant prostate cancer.

Promising Early Activity With VERU-111 Provides Proof-of-Concept for Phase III Research in mCRPC

May 05, 2020

Results from the phase Ib/II study of VERU-111 in patients with metastatic castration-resistant prostate cancer have prompted plans to meet with the FDA in the third quarter of 2020 to discuss the trial design for a phase III clinical trial of VERU-111 for this indication.

FDA Approval Sought for Relugolix in Advanced Prostate Cancer

April 21, 2020

"We made the decision to prioritize this NDA submission and potentially accelerate the availability of an oral treatment option for men with advanced prostate cancer...”

Combining Immune Checkpoint and Androgen Receptor Inhibitors Yields Positive Responses for mCRPC

April 11, 2020

Pembrolizumab plus enzalutamide in castration- resistant prostate cancer that exhibited enzalutamide resistance led to positive antitumor signals and a favorable safety profile, according to results of the phase II KEYNOTE-199 trial presented at the 2020 Genitourinary Cancers Symposium.

FDA Grants Pembrolizumab Priority Review for TMB-High Tumors

April 07, 2020

The FDA has accepted and granted a priority review to a supplemental Biologics License Application for pembrolizumab for the treatment of adult and pediatric patients with unresectable or metastatic solid tumors with tissue tumor mutational burden-high who have progressed following prior treatment and who have no satisfactory alternative treatment options.

Real-World PSA Response Data Similar to Clinical Trials in Prostate Cancer

April 07, 2020

Stephen J. Freedland, MD, discusses real-world data for enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer compared with data from the phase III PREVAIL study.

Darolutamide Trial Evaluates Noninferiority to Standard Care in Intermediate-Risk Prostate Cancer

April 06, 2020

External Beam Radiation therapy with or without androgen deprivation therapy or surgery are the standards of care for men with intermediate-risk prostate cancer, but the adverse events associated with the treatments, delayed testosterone recovery and prolonged erectile dysfunction, are challenges.

Chemotherapy Toxicity Correlates With Nutritional Factors in Solid Tumors

March 30, 2020

An association was found between a lower risk of grade 3 or higher chemotherapy toxicity with higher body mass indexes and normal albumin, a protein made in the liver, levels in older adult patients with solid tumors, according to an analysis of a prospective, multicenter study.

COVID-19 Presents an Opportunity for Precision Medicine to Play Expanded Role in Care

March 30, 2020

A sudden surge in the cases of COVID-19 due to pandemic, along with efforts to contain it, has led to multiple challenges that no country has experienced in the last several decades. The global pandemic from COVID-19 poses a unique set of challenges not only for patients with cancer who need their treatment, but also for caregivers, oncologists, and the overall care team.